Pretreatment levels of serum vascular endothelial growth factor do not correlate with outcome in patients with locally advanced cervical cancer

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 3, 2011, Pages 699-702

  Katanyoo, Kanyarat ^a   Chantarasri, Amnat ^b   Chongtanakon, Marisa ^a   Rongsriyam, Kanisa ^a   Tantivatana, Thanatip ^a  

^a Department of Radiology   (Thailand)

^b NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

Author keywords

Clinicopathological parameters; Locally advanced cervical cancer; Radiotherapy; Serum VEGF

Indexed keywords

EID: 79958865086     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Bachtiary B, Selzer E, Knocke TH, et al. (2002). Serum VEGF levels in patients undergoing primary radiotherapy for cervical cancer: impact on progression-free survival. Cancer Lett, 179, 197-203.
2. Burger RA. (2010). Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol, 21, 3-11.
3. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC 2010). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews 2010, Issue 1.Art. No.: CD008285. DOI: 10.1002/14651858.CD008285.
4. Ferrara N, Henzel WJ. (1989). Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun, 161, 851-9.
5. Folkman J. (1992). The role of angiogenesis in tumor growth. Semin Cancer Biol, 3, 65-71.
6. Frumovitz M, Sood AK. (2007). Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol, 104, 768-78.
7. Fujimoto J, Sakaguchi H, Hirose R, et al. (1999). Expression of vascular endothelial growth factor (VEGF) and its mRNA in uterine cervical cancers. Br J Cancer, 80, 827-33.
8. Gadducci A, Tana R, Cosio S, et al. (2007). The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature. Crit Rev Oncol Hematol, 66, 10-20.
9. Kudelka AP, Levy T, Verschraegen CF, et al. (1997). A phase I study of TNP-470 administrated to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res, 3, 1501-5.
10. Kudelka AP, Verschraegen CF, Loyer E. (1998). Complete remission of metastatic cervical cancer with the angiogenesis in hibitor TNP-470. N Engl J Med, 338, 991-2.
11. Lebrecht A, Ludwig E, Huber A, et al. (2002). Serum vascular endothelial growth factor and serum leptin in patients with cervical cancer. Gynecol Oncol, 85, 32-5.
12. Mitsuhashi A, Suzuka K, Yamazawa K, et al. (2005). Serum vascular endothelial growth factor (VEGF) and VEGF-C levels as tumor markers in patients with cervical carcinoma. Cancer, 103, 724-30.
13. Moon HS, Kim SC, Aha JJ, et al. (2000). Concentration of vascular endothelial growth factor (VEGF) and transforming growth factor-beta1 (TGF-beta1) in the serum of patients with cervical cancer: prediction of response. Int J Gynecol Cancer, 10, 151-6.
14. Parkin DM, Bray F, Ferlay J, et al. (2002). Global cancer statistics. CA Cancer J Clin, 55, 74-108.
15. Santin AD, Hermonat PL, Ravaggi A, et al. (1999). Secretion of vascular endothelial growth factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix. Obstet Gynecol, 94, 78-82.
16. Srivastava S, Gupta A, Agarwal GG, et al. (2009). Correlation of serum vascular endothelial growth factor with clinicopathological parameters in cervical cancer. Biosci Trends, 3, 144-50.
17. Senger DR, Connolly DT, Van de Water L, et al. (1990). Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res, 50, 1774-8.
18. Sriplung H, Wiangnon S, Sontipong S, et al. (2006). Cancer incidence trends in Thailand, 1989-2000. Asian Pac J Cancer Prev, 7, 239-44.
19. Ugurel S, Rappl G, Tilgen W, et al. (2001). Increased serum concentration of angiogenetic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol, 19, 577-83.
20. Zusterzeel PLM, Span PN, Dijksterhuis MGK, et al. (2009). Serum vascular endothelial growth factor: a prognostic factor in cervical cancer. J Cancer Res Clin Oncol, 135, 283-90.